Vanguard Group Inc Biovie Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BIVI
# of Institutions
45Shares Held
4.73MCall Options Held
17.2KPut Options Held
27K-
Altium Capital Management LP New York, NY1.98MShares$5.49 Million0.42% of portfolio
-
Sabby Management, LLC Upper Saddle River, NJ733KShares$2.03 Million19.26% of portfolio
-
Swisspartners Ltd. Vaduz, N2294KShares$815,3382.92% of portfolio
-
Geode Capital Management, LLC Boston, MA232KShares$641,6870.0% of portfolio
-
Jane Street Group, LLC New York, NY176KShares$488,1730.0% of portfolio
About BIOVIE INC.
- Ticker BIVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,165,300
- Market Cap $83.6M
- Description
- BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...